CVS Caremark Expands Biosimilar Formulary, Boosting Margin Outlook

What happened

CVS Health announced updates to its commercial template formularies to prefer interchangeable biosimilars over reference brands starting July 2026, expected to deliver significant client savings while maintaining clinical standards. This aligns with CVS's strategy through Cordavis to drive biosimilar adoption and supports the company's transparent pricing shift (TrueCost). The move should enhance drug trend moderation, improve client retention, and contribute to margin improvement, reinforcing management's raised 2025 adjusted EPS guidance. However, the impact is incremental and must be weighed against ongoing PBM regulatory risk and litigation overhangs.

Implication

The biosimilar expansion is a short-term positive, supporting drug cost trends and client savings, which should aid CVS's transparent pricing model and margin recovery. However, the stock's re-rating depends on sustained execution across restructuring, medical cost stabilization, and resolution of PBM regulation and litigation. Investors should view this as confirming the thesis but not a catalyst for significant multiple expansion.

Thesis delta

The thesis remains BUY, with this news reinforcing the positive outlook on biosimilar adoption and margin improvement. No material change to the investment case; the key watch items (medical utilization, PBM regulation, litigation, restructuring savings) remain unchanged. The delta is a modest increase in confidence that CVS can achieve its 2025 guidance and margin goals.